Glycodelin A, also known as placental protein-14, is a multifunctional glycosylated protein secreted by the uterine endometrium during the early phases of pregnancy. It is a known suppressor of T cell proliferation, inducer of T cell apoptosis, and inhibitor of sperm zona binding. Unlike in contraceptive activity, where the glycans on the molecule have been shown to play a crucial role, mutagenesis of the asparagines at sites of N-linked glycosylation (Asn 28 and Asn 63 ) to glutamine shows that the apoptogenic activity of glycodelin A is executed by the protein backbone. Glycosylation at Asn 28 appears to play a role in the extracellular secretion of the molecule, as mutation of Asn 28 resulted in a significant decrease in the amount of secreted protein, and loss of both glycosylation sites reduced the secretion drastically. Our results also suggest that the loss of glycosylation does not affect the dimerization status of the molecule.Glycodelin A (GdA), 1 also known as PP14 (placental protein-14), is a glycosylated dimeric 162-amino acid protein secreted by human endometrium in the late secretory phase of the menstrual cycle and in the early phase of pregnancy under the regulation of the hormone progesterone (1). Glycodelin is glycosylated at two of the three putative glycosylation sites (Asn 28 and Asn 63 ) (2). Observations of several research groups suggest that GdA is immunosuppressive in function (3), and previous studies from our laboratory indicate that this effect is due to its capacity to induce apoptosis in T cells (4). Interestingly, glycodelin S (GdS), another isoform of glycodelin synthesized by the seminal vesicles and accumulating in the seminal plasma, is not apoptogenic (26) even though both isoforms share the same amino acid sequence. As the glycans on both isoforms are different and as glycosylation has been demonstrated to play an important role in the contraceptive activity of GdA (13), it appeared logical to investigate the relevance of glycosylation to the apoptogenic function. However, attempts to deglycosylate GdA and GdS under native conditions using enzymes were not successful. Therefore, we resorted to molecular biology approaches to mutate the glycosylation sites and to express the protein in a eukaryotic system. The functional analysis of protein thus expressed proves that the apoptogenic activity of the molecule resides in its protein backbone, with the oligosaccharides being either permissive or non-permissive in the manifestation of this observed property. Furthermore, we have demonstrated that glycosylation at Asn 28 plays a role in the secretory rate of the protein, as the mutagenesis of the same drastically reduces protein secretion. We also have evidence to suggest that lack of glycosylation does not compromise the dimerization state of the molecule.
EXPERIMENTAL PROCEDURESCells and Cell Lines-Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood collected from healthy volunteers (male and female, 25-49 years old) using HISTOPAQUE-1077 (Sigma) accor...